Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research-The ConPhyMP-Guidelines

被引:141
作者
Heinrich, Michael [1 ]
Jalil, Banaz [1 ]
Abdel-Tawab, Mona [2 ]
Echeverria, Javier [3 ]
Kulic, Zarko [4 ]
McGaw, Lyndy J. [5 ]
Pezzuto, John M. [6 ]
Potterat, Olivier [7 ]
Wang, Jia-Bo [8 ]
机构
[1] UCL Sch Pharm, Pharmacognosy & Phytotherapy, London, England
[2] Goethe Univ Frankfurt, Germany Inst Pharmaceut Chem, Cent Lab German Pharmacists, Frankfurt, Germany
[3] Univ Santiago Chile, Fac Quim & Biol, Dept Ciencias Ambiente, Santiago, Chile
[4] Dr Willmar Schwabe GmbH & Co KG, Preclin Res & Dev, Karlsruhe, Germany
[5] Univ Pretoria, Fac Vet Sci, Dept Paraclin Sci, Phytomed Programme, Pretoria, South Africa
[6] Western New England Univ, Coll Pharm & Hlth Sci, Springfield, MA USA
[7] Univ Basel, Div Pharmaceut Biol, Basel, Switzerland
[8] Capital Med Univ, Sch Tradit Chinese Med, Beijing, Peoples R China
关键词
Best practice; extract characterisation; medicinal plant; analytical methods; phytochemical analysis; HPTLC; HPLC; EXPERIMENTAL-DESIGN;
D O I
10.3389/fphar.2022.953205
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Research on medicinal plants and extracts derived from them differs from studies performed with single compounds. Extracts obtained from plants, algae, fungi, lichens or animals pose some unique challenges: they are multicomponent mixtures of active, partially active and inactive substances, and the activity is often not exerted on a single target. Their composition varies depending on the method of preparation and the plant materials used. This complexity and variability impact the reproducibility and interpretation of pharmacological, toxicological and clinical research. Objectives: This project develops best practice guidelines to ensure reproducibility and accurate interpretations of studies using medicinal plant extracts. The focus is on herbal extracts used in pharmacological, toxicological, and clinical/intervention research. Specifically, the consensus-based statement focuses on defining requirements for: 1) Describing the plant material/herbal substances, herbal extracts and herbal medicinal products used in these studies, and 2) Conducting and reporting the phytochemical analysis of the plant extracts used in these studies in a reproducible and transparent way. The process and methods: We developed the guidelines through the following process: 1) The distinction between the three main types of extracts (extract types A, B, and C), initially conceptualised by the lead author (MH), led the development of the project as such; 2) A survey among researchers of medicinal plants to gather global perspectives, opportunities, and overarching challenges faced in characterising medicinal plant extracts under different laboratory infrastructures. The survey responses were central to developing the guidelines and were reviewed by the core group; 3) A core group of 9 experts met monthly to develop the guidelines through a Delphi process; and. 4) The final draft guidelines, endorsed by the core group, were also distributed for feedback and approval to an extended advisory group of 20 experts, including many journal editors. Outcome: The primary outcome is the "Consensus statement on the Phytochemical Characterisation of Medicinal Plant extracts " (ConPhyMP) which defines the best practice for reporting the starting plant materials and the chemical methods recommended for defining the chemical compositions of the plant extracts used in such studies. The checklist is intended to be an orientation for authors in medicinal plant research as well as peer reviewers and editors assessing such research for publication.
引用
收藏
页数:20
相关论文
共 24 条
[1]   Improving the quality of reporting of randomized controlled trials - The CONSORT statement [J].
Begg, C ;
Cho, M ;
Eastwood, S ;
Horton, R ;
Moher, D ;
Olkin, I ;
Pitkin, R ;
Rennie, D ;
Schulz, KF ;
Simel, D ;
Stroup, DF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (08) :637-639
[2]  
Braun V., 2006, Qual Res Psychol, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA, DOI 10.1007/978-981-10-2779-6103-1, https://doi.org/10.1191/1478088706qp063oa]
[3]  
BSC, 2021, BEST PRACT MED PLANT
[4]  
Burn JH, 1930, J PHARMACOL EXP THER, V39, P221
[5]  
Cai ZJ, 1999, WHO TECH REP SER, V887, P1
[6]   Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica [J].
Chan, Kelvin ;
Shaw, Debbie ;
Simmonds, Monique S. J. ;
Leon, Christine J. ;
Xu, Qihe ;
Lu, Aiping ;
Sutherland, Ian ;
Ignatova, Svetlana ;
Zhu, You-Ping ;
Verpoorte, Rob ;
Williamson, Elizabeth M. ;
Duez, Pierre .
JOURNAL OF ETHNOPHARMACOLOGY, 2012, 140 (03) :469-475
[7]   Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies [J].
Chou, Ting-Chao .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :621-681
[8]   Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers [J].
Curtis, Michael J. ;
Alexander, Steve ;
Cirino, Giuseppe ;
Docherty, James R. ;
George, Christopher H. ;
Giembycz, Mark A. ;
Hoyer, Daniel ;
Insel, Paul A. ;
Izzo, Angelo A. ;
Ji, Yong ;
MacEwan, David J. ;
Sobey, Christopher G. ;
Stanford, S. Clare ;
Teixeira, Mauro M. ;
Wonnacott, Sue ;
Ahluwalia, Amrita .
BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (07) :987-993
[9]  
GA, 2021, BEST PRACT MED PLANT
[10]  
Heinrich M., 2017, Fundamentals of Pharmacognosy and Phytotherapy E-Book